Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

BACKGROUND: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combina...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Brown, Lauren J, Weppler, Alison, Bhave, Prachi, Allayous, Clara, Patrinely Jr, J. Randall, Ott, Patrick, Sandhu, Shahneen, Haydon, Andrew, Lebbe, Celeste, Johnson, Douglas B, Long, Georgina V, Menzies, Alexander A, Carlino, Matteo S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Clinical/Translational Cancer Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108669/
https://ncbi.nlm.nih.gov/pubmed/33963010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002121
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller